MTOR and hepatocellular carcinoma: GPD1L, through its involvement in lipid metabolism and its interaction with AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling, plays a critical role in integrating metabolic and signalling cues that contribute to HCC development and progression [6,25].